ANTI MOG ANTIBODY VERIFICATION

Small field of view axial and coronal T2WI with fat saturation and fat saturated post contrasted axial and coronal images were obtained for orbital evaluation. For brain MRI, sagittal T1WI, axial fast spin-echo T2WI, axial/sagittal fast spin-echo FLAIR, and in some cases sagittal 3D FLAIR images, axial diffusion and ADC mapped images followed by post-contrast axial and coronal T1WI were analyzed. The MR exams were performed with different scanners at either 1.5T or 3T magnetic strength: Philips Healthcare (Best, the Netherlands), GE Healthcare (Milwaukee, Wisconsin), and Siemens (Erlangen, Germany). inflammatory attack(s) of the optic nerve, spinal cord or brain, including the brainstem and area postrema attacks ( 2).Īll MOG positive patients were included (n=26) and 25 AQP4 positive patients with matching age and sex were collected from the records.Īll subjects provided consent to participate in this study, which was approved by the Johns Hopkins University institutional review board. AQP4 antibody seropositivity by ELISA( four patients were tested subsequently using cell-based assay due to negative ELISA results despite strong clinical suspicion) 2. Inclusion criteria for AQP4 seropositive NMOSD were based on the 2015 International Panel on NMOSD Diagnosis which requires 1. We did not necessarily exclude patients who also met criteria for multiple sclerosis (MS) as there is no consensus-based distinction between MS and MOGAD. inflammatory attack(s) of the optic nerve, spinal cord or brain. MOG antibody seropositivity by live cell-based assay with IgG1 secondary antibody from the Mayo Medical Lab, Quest Diagnostics or the Oxford University Neuroimmunology Laboratory (UK) and 2. Inclusion criteria for MOG antibody disease were: 1. This is a retrospective analysis of patients recruited in person from the Johns Hopkins Hospital NMO clinic between 2015-2018 or recruited remotely through review of records by the principle investigator (ML). The goal is to confirm known MRI features or identify new ones in NMOSD that can prompt serological testing for the MOG antibody. In this study we retrospectively reviewed the MR imaging findings of MOG and AQP4 antibody seropositive NMOSD and compared our findings with those that have been reported. Conus medullaris is a frequent target of attack in MOGAD patients compared to the cervical and thoracic spinal cord in AQP4 NMOSD ( 13). Despite the fact that 50% of MOG patients relapse with transverse myelitis ( 7, 11, 12), they are less likely to experience cord necrosis or atrophy as a sequelae, relative to AQP4 patients ( 13– 15). Longitudinally extensive optic nerve lesions are common in both MOGAD and AQP4 seropositive NMOSD, ( 9, 10) while posterior nerve segment and chiasmatic involvement appears to be more unique to AQP4 NMOSD ( 10). MRI is instrumental in distinguishing NMOSD from multiple sclerosis (MS), but initial MR reports in MOG antibody disease identified both overlapping and unique features compared with AQP4 NMOSD ( 5, 8).

Compared to AQP4 seropositive patients, MOG antibody disease (MOGAD) is thought to more commonly affect young Caucasian males, with a relatively better long-term clinical outcome ( 6, 7). Among NMOSD patients who test negative for the AQP4 antibody, up to 42% test positive for an antibody against myelin oligodendrocyte glycoprotein antibody (MOG) ( 4, 5). ( 2) Up to 87% of NMOSD patients harbor a serological antibody to the aquaporin-4 (AQP4) water channel ( 3). In 2015, the spectrum was defined to include 6 core features namely, optic nerves, spinal cord, area postrema, brain stem, diencephalic structures and cerebral hemispheres. It was thought to only involve the optic nerves and spinal cord leading to blindness and paralysis ( 1). If you cannot find the antibody you're looking for, contact us today to develop custom antibodies for specific targets, species and applications.Neuromyelitis optica spectrum disorder (NMOSD) is rare autoimmune central nervous system (CNS) disease.

ANTI MOG ANTIBODY VERIFICATION

Antibodies with Advanced Verification data have been validated for specificity to ensure that the antibody binds to the antigen stated. īrowse primary antibodies for WB, Flow, IHC, ICC/IF, ELISA, IP, and other applications. Choose from 1 of 16 MOG antibodies, which have been validated in experiments with 5 publications and 53 images featured in our data gallery.īrowse primary antibodies for WB, Flow, IHC. Find the MOG antibody that fits your needs. These antibodies have been verified by Relative expression to confirm specificity to MOG. Our MOG polyclonal, recombinant monoclonal and monoclonal antibodies are developed in Rabbit, Mouse and Goat. These antibodies target MOG in Human, Mouse, Rat samples. Antibodies that detect MOG can be used in several scientific applications, including Western Blot, Immunohistochemistry, ELISA, Immunocytochemistry and Flow Cytometry.

Anti mog antibody